Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.

Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Bötzel K, Ertl-Wagner B, Huppertz HJ, Ricard I, Höglinger GU; PROMESA Study Group.

Lancet Neurol. 2019 Aug;18(8):724-735. doi: 10.1016/S1474-4422(19)30141-3. Epub 2019 Jul 2.

PMID:
31278067
2.

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Heintges T, Kahl C, Kullmann F, Scheithauer W, Moehler M, Jelas I, Modest DP, Westphalen CB, von Einem JC, Michl M, Heinemann V.

Eur J Cancer. 2019 Jan;106:115-125. doi: 10.1016/j.ejca.2018.10.001. Epub 2018 Nov 27.

PMID:
30496943
3.

Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.

Stintzing S, Ivanova B, Ricard I, Jung A, Kirchner T, Tannapfel A, Juette H, Hegewisch-Becker S, Arnold D, Reinacher-Schick A.

Front Oncol. 2018 Nov 8;8:474. doi: 10.3389/fonc.2018.00474. eCollection 2018.

4.

Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial.

Hofmann FO, Holch JW, Heinemann V, Ricard I, Reiser MF, Baumann AB, Hesse N, D'Anastasi M, Modest DP, Stintzing S, Sommer WH.

Eur J Radiol. 2018 Mar;100:124-129. doi: 10.1016/j.ejrad.2018.01.006. Epub 2018 Jan 6.

PMID:
29496069
5.

Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.

Modest DP, Denecke T, Pratschke J, Ricard I, Lang H, Bemelmans M, Becker T, Rentsch M, Seehofer D, Bruns CJ, Gebauer B, Modest HI, Held S, Folprecht G, Heinemann V, Neumann UP.

Eur J Cancer. 2018 Jan;88:77-86. doi: 10.1016/j.ejca.2017.10.028. Epub 2017 Nov 28.

PMID:
29195117
6.

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton.

Song OR, Queval CJ, Iantomasi R, Delorme V, Marion S, Veyron-Churlet R, Werkmeister E, Popoff M, Ricard I, Jouny S, Deboosere N, Lafont F, Baulard A, Yeramian E, Marsollier L, Hoffmann E, Brodin P.

EMBO Rep. 2018 Jan;19(1):29-42. doi: 10.15252/embr.201744371. Epub 2017 Nov 15.

7.

Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.

Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Kullmann F, Scheithauer W, Scholz M, Müller S, Link H, Rost A, Höffkes HG, Moehler M, Lindig RU, Miller-Phillips L, Kirchner T, Jung A, von Einem JC, Modest DP, Heinemann V.

Int J Cancer. 2018 Mar 1;142(5):1047-1055. doi: 10.1002/ijc.31114. Epub 2017 Nov 7.

8.

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).

Modest DP, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Westphalen CB, Holch JW, von Einem JC, Held S, Heinemann V; for FIRE-3/AIOKRK0306-investigators.

Eur J Cancer. 2017 Oct;84:262-269. doi: 10.1016/j.ejca.2017.07.030. Epub 2017 Aug 23.

PMID:
28843184
9.

Predictors of cerebrovascular events at mid-term after transcatheter aortic valve implantation - Results from EVERY-TAVI registry.

Jochheim D, Zadrozny M, Ricard I, Sadry TM, Theiss H, Baquet M, Schwarz F, Bauer A, Khandoga A, Sadoni S, Pichlmaier M, Hausleiter J, Hagl C, Massberg S, Mehilli J.

Int J Cardiol. 2017 Oct 1;244:106-111. doi: 10.1016/j.ijcard.2017.03.003.

PMID:
28784441
10.

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone.

Song OR, Kim HB, Jouny S, Ricard I, Vandeputte A, Deboosere N, Marion E, Queval CJ, Lesport P, Bourinet E, Henrion D, Oh SB, Lebon G, Sandoz G, Yeramian E, Marsollier L, Brodin P.

Toxins (Basel). 2017 Jul 18;9(7). pii: E227. doi: 10.3390/toxins9070227.

11.

Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer.

Herbst A, Vdovin N, Gacesa S, Ofner A, Philipp A, Nagel D, Holdt LM, Op den Winkel M, Heinemann V, Stieber P, Graeven U, Reinacher-Schick A, Arnold D, Ricard I, Mansmann U, Hegewisch-Becker S, Kolligs FT.

Int J Cancer. 2017 May 1;140(9):2134-2144. doi: 10.1002/ijc.30625. Epub 2017 Feb 22. Erratum in: Int J Cancer. 2018 Feb 1;142(3):E1.

12.

The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.

Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V.

Eur J Cancer. 2017 Jan;70:87-98. doi: 10.1016/j.ejca.2016.10.007. Epub 2016 Nov 29.

PMID:
27907852
13.

Erratum to: The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach.

Levin J, Maaß S, Schuberth M, Respondek G, Paul F, Mansmann U, Oertel WH, Lorenzl S, Krismer F, Seppi K, Poewe W, Wenning G, Berg D, Claßen J, Ebersbach G, Eggert K, Kassubek J, Lipp A, Löhle M, Mollenhauer B, Münchau A, Südmeyer M, Blankenstein C, Eberhardt C, Ertl-Wagner B, Heise H, Ricard I; PROMESA study group, Giese A, Bötzel K, Höglinger G.

J Neural Transm (Vienna). 2016 Nov;123(11):1357-1358. No abstract available.

PMID:
27562771
14.

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.

Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A.

Ann Oncol. 2016 Sep;27(9):1746-53. doi: 10.1093/annonc/mdw261. Epub 2016 Jun 29.

15.

Yersinia pestis requires the 2-component regulatory system OmpR-EnvZ to resist innate immunity during the early and late stages of plague.

Reboul A, Lemaître N, Titecat M, Merchez M, Deloison G, Ricard I, Pradel E, Marceau M, Sebbane F.

J Infect Dis. 2014 Nov 1;210(9):1367-75. doi: 10.1093/infdis/jiu274. Epub 2014 May 9.

PMID:
24813471
16.

New insights into how Yersinia pestis adapts to its mammalian host during bubonic plague.

Pradel E, Lemaître N, Merchez M, Ricard I, Reboul A, Dewitte A, Sebbane F.

PLoS Pathog. 2014 Mar 27;10(3):e1004029. doi: 10.1371/journal.ppat.1004029. eCollection 2014 Mar.

17.

Inheritance of the lysozyme inhibitor Ivy was an important evolutionary step by Yersinia pestis to avoid the host innate immune response.

Derbise A, Pierre F, Merchez M, Pradel E, Laouami S, Ricard I, Sirard JC, Fritz J, Lemaître N, Akinbi H, Boneca IG, Sebbane F.

J Infect Dis. 2013 May 15;207(10):1535-43. doi: 10.1093/infdis/jit057. Epub 2013 Feb 12.

PMID:
23402825
18.

Efficacy of ciprofloxacin-gentamicin combination therapy in murine bubonic plague.

Lemaître N, Ricard I, Pradel E, Foligné B, Courcol R, Simonet M, Sebbane F.

PLoS One. 2012;7(12):e52503. doi: 10.1371/journal.pone.0052503. Epub 2012 Dec 20.

19.

Drug-eluting versus bare-metal stents in large coronary arteries.

Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M; BASKET–PROVE Study Group.

N Engl J Med. 2010 Dec 9;363(24):2310-9. doi: 10.1056/NEJMoa1009406. Epub 2010 Nov 16.

20.
21.

Phenotypic analysis of Yersinia pseudotuberculosis 32777 response regulator mutants: new insights into two-component system regulon plasticity in bacteria.

Flamez C, Ricard I, Arafah S, Simonet M, Marceau M.

Int J Med Microbiol. 2008 Apr;298(3-4):193-207. Epub 2007 Aug 31.

PMID:
17765656
22.

Double staining of Plasmodium falciparum nucleic acids with hydroethidine and thiazole orange for cell cycle stage analysis by flow cytometry.

Jouin H, Daher W, Khalife J, Ricard I, Puijalon OM, Capron M, Dive D.

Cytometry A. 2004 Jan;57(1):34-8.

23.

Screening of Plasmodium falciparum iron superoxide dismutase inhibitors and accuracy of the SOD-assays.

Soulère L, Delplace P, Davioud-Charvet E, Py S, Sergheraert C, Périé J, Ricard I, Hoffmann P, Dive D.

Bioorg Med Chem. 2003 Nov 17;11(23):4941-4.

PMID:
14604655
24.

The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.

Béliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pépin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E.

Clin Cancer Res. 2002 Apr;8(4):1242-50.

25.

Ultrastructural and molecular characterization of Pneumocystis carinii isolated from a rhesus monkey (Macaca mulatta).

Durand-Joly I, Wakefield AE, Palmer RJ, Denis CM, Creusy C, Fleurisse L, Ricard I, Gut JP, Dei-Cas E.

Med Mycol. 2000 Feb;38(1):61-72.

PMID:
10746229
26.

First steps in the purification and characterization of a Pichia anomala killer toxin.

Guyard C, Séguy N, Lange M, Ricard I, Polonelli L, Cailliez JC.

J Eukaryot Microbiol. 1999 Sep-Oct;46(5):144S. No abstract available.

PMID:
10519293
27.

Pneumocystis carinii growth kinetics in culture systems and in hosts: involvement of each life cycle parasite stage.

Aliouat el-M, Dujardin L, Martinez A, Duriez T, Ricard I, Dei-Cas E.

J Eukaryot Microbiol. 1999 Sep-Oct;46(5):116S-117S. No abstract available.

PMID:
10519275
31.

Supplemental Content

Loading ...
Support Center